Original White Feather Rice Intranet
Highlights
According to data from Minenet, the sales of qi and blood nourishing Chinese patent medicines will exceed 15 billion yuan in physical pharmacies in key provinces in 2023. Among them, as one of the main subcategories, the sales scale of blood-tonifying Chinese patent medicine has been close to 10 billion yuan, a year-on-year increase of 17.15%, and from the perspective of provincial and municipal patterns, Guangdong, Zhejiang, and Shandong sales have exceeded 1 billion yuan. From the TOP20 point of view, 6 billion varieties are "kings", new 1 billion single products are born, and the two exclusive products have doubled, with Dong'e Ejiao, Hongjitang, Zhongjing Wanxi Pharmaceutical, etc. on the list. Since 2019, only 3 new drugs have been approved for clinical trials.
Blood-tonifying Chinese patent medicines sold nearly 10 billion, and the three provinces of Guangdong, Zhejiang, and Shandong were hot
Quarterly sales of blood-replenishing Chinese patent medicines in physical pharmacies in key provinces in 2023 (unit: 100 million yuan)
According to data from Minenet, the sales of qi-replenishing and blood-replenishing Chinese patent medicines in physical pharmacies in key provinces will exceed 15 billion yuan in 2023, of which blood-tonifying Chinese patent medicines, as one of the main subcategories, have a sales scale of nearly 10 billion yuan, a year-on-year increase of 17.15%. From the perspective of enterprise structure, Dong'e Ejiao, Shandong Fupai Ejiao, and Shandong Hongjitang Pharmaceutical Group rank among the top three. From the perspective of provincial and municipal patterns, the sales scale of Guangdong, Zhejiang and Shandong all exceeded 1 billion yuan.
From the perspective of the nature of prescription of Chinese patent medicines for blood replenishment, both OTC and RX have a growth rate of more than 10%, and the OTC market is the largest, accounting for more than 90%. From the perspective of dosage forms, the total market share of the two major dosage forms of extract/decoction and solution accounts for more than 90%.
6 billion varieties lead, the two exclusive products doubled, Dong'e Ejiao, Hongjitang ...... List
2023 Top 20 Chinese patent medicine products for blood replenishment in physical pharmacies in key provinces (unit: 100 million yuan)
Note: Sales of less than 100 million yuan are expressed as *
The sales of 4 products exceeded 100 million yuan, a decrease of 2 compared to 2022. Ejiao continued to lead the way, with a sales scale of more than 6 billion yuan, and compound Ejiao paste became the second single product of 1 billion yuan.
The 12 exclusive products are compound Ejiao Pulp (Dong'e Ejiao), Pomegranate Blood Sugar Supplement Pulp (Xinjiang Uygur Pharmaceutical), Shengxuebao Mixture (Tsinghua Deren Xi'an Xingfu Pharmaceutical), Ejiao Astragalus Oral Liquid (Hebei Junlin Pharmaceutical), Compound Hongyi Blood Replenishing Oral Liquid (Xiangyu Pharmaceutical), Yixuesheng Capsule (Jilin Sanjiu Jin Rehabilitation Pharmaceutical), Yiqi Weixue Granules and Yiqi Weixue Capsule (Guangdong Red Coral Pharmaceutical), Yixuesheng Tablets (Jilin Jierji Pharmaceutical), Gui Spleen Granules (Zhejiang Aisheng Pharmaceutical), Yangxue Drink Oral Liquid (Jilin Aodong Group Liyuan Pharmaceutical) and Shengxuening Tablets (Wuhan United Pharmaceutical), among them, the growth rate of Yixuesheng Capsule (197.53%) and Gui Spleen Granules (122.74%) doubled, and the growth rate of Yiqi Weixue Granules, Yixuesheng Tablets and Ejiao Astragalus Oral Liquid exceeded 50%.
2023 TOP20 Chinese patent medicine brands for blood replenishment in physical pharmacies in key provinces (unit: 100 million yuan)
Note: Sales of less than 100 million yuan are indicated by *
Among the top 20 brands, 8 have sales of more than 100 million yuan. From the perspective of growth rate, Jilin Sanjiu Jinrehab Pharmaceutical's Yixuesheng Capsule and Hunan Dongjian Pharmaceutical's Ejiao doubled, Dong'e Ejiao's Ejiao and compound Ejiao pulp, Shandong Hongjitang Pharmaceutical Group's Ejiao, Shandong Fupai Pharmaceutical's Ejiao Blood Replenishing Oral Liquid, Zhongjing Wanxi Pharmaceutical's Gui Spleen Pill, Jiuzhitang's Ejiao and Gui Spleen Pill (Concentrated Pill) and other 11 brands have double-digit growth rates, among them, Hunan Dongjian Pharmaceutical's Ejiao and Zhongjing Wanxi Pharmaceutical's Gui Spleen Pill have entered the top ten with rapid growth.
The main effects of Ejiao are blood replenishment, hemostasis, nourishing yin and moisturizing dryness, and is used for blood deficiency and chlorosis, dizziness, palpitations, muscle weakness, and a variety of bleeding syndromes, yin deficiency syndromes and dryness syndromes. In 2023, the sales scale of Ejiao in physical pharmacies in key provinces will exceed 6 billion yuan, a year-on-year increase of more than 10%, Dong'e Ejiao has the largest market share, and Shandong Hongjitang Pharmaceutical Group will exceed 1 billion yuan. Dong'e Ejiao said that the company is to grasp the "breakthrough" on the point, promote the integration of the three industries, focus on the supply of raw materials, the main business of Ejiao, and the health care experience; the second is to grasp the "expansion" online, promote the extension of the chain, promote the innovation of medical research on glue medicinal materials such as deer horn gum, tortoiseshell gum, and sea dragon gum, accelerate the layout of andrology products such as Hailong gum oral liquid, turtle and deer deer horn gum, and explore the second growth curve; In the future, the company will accelerate business remodeling, continue to further promote the two-wheel drive business model, adhere to the principle of consolidating the foundation and opening up new ones, maintain stable growth, and actively expand to other tonic categories such as men's tonic based on the large category of qi and blood, so as to meet the nourishing and health needs of more consumers. A few days ago, the company disclosed the results of the first quarter of 2024, with an operating income of 1.453 billion yuan, a year-on-year increase of 35.95%, and a net profit of 353 million yuan, a year-on-year increase of 53.43%.
Gui Spleen Pill is beneficial to qi and blood, spleen and heart, and is used for heart and spleen deficiency, symptoms such as palpitations, forgetfulness, insomnia, night sweats, deficiency and heat, etc. The product has 193 companies with production approvals, and it is the most competitive variety in the TOP20, and the market size of physical pharmacies in key provinces will exceed 100 million yuan in 2023, with Zhongjing Wanxi Pharmaceutical having the largest market share, with a growth rate of more than 20% to enter the top 10 brands.
The new 1 billion single products are launched, and Shenwei sprints to Class 1 new drugs
In recent years, the clinical situation of the approval of blood-tonifying Chinese patent medicines
Source: Minenet China Declaration Progress (MED) database
Since 2019, no products have been approved for marketing and production under review, and only 3 new drugs have been approved for clinical trials, among which Dong'e Ejiao's compound Ejiao paste has been approved for clinical trials this year as a class 2.3 new drug.
Source: Minenet Project Progress Database
Compound Ejiao Paste is the exclusive variety of Dong'e Ejiao, which originated from the "Liangyi Cream" of the first party of the Ming Dynasty's Qi and Blood Double Supplement, "Jingyue Quanshu", and has been inherited for more than 400 years, nourishing qi and nourishing blood, treating dizziness, insomnia and anemia. In February this year, the product was approved for clinical use in new indications, mainly to clarify the clinical efficacy of the product for new indications, provide academic support for market development, and enhance market competitiveness.
Sources: Minenet database, company announcements, etc
Note: The competition pattern of Chinese patent medicine terminals in physical pharmacies in key provinces of Minenet is an enlarged version of the Chinese patent medicine database of urban physical pharmacies covering all physical pharmacies in 17 provinces and 4 municipalities directly under the central government, and conducting continuous testing of all categories, and the above sales are calculated based on the average retail price of products in the terminal. If there is any omission, please correct it!